In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Related News Articles

Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
Beth Heinz, senior vice president, Women’s and Children’s Services at Yale New Haven Health, and Cheri Johnson, chief nursing officer, Woman’s Hospital in…
Blog
One of our best strategies to address the unique behavioral health challenges and demands of pregnant women and new mothers is recognizing that mental health…
Headline
Rep. Robin Kelly, D-Ill., member of the Health Subcommittee of the Energy and Commerce Committee and chair of the Congressional Black Caucus Health Braintrust…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…